An observational study in Squamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and Neck, sponsored by Bristol-Myers Squibb. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-02.
Sponsored by Bristol-Myers Squibb · Observational
A prospective real world evidence study of Nivolumab use in France in patient with recurrent or metastatic squamous cell carcinoma of the Head and Neck progressing on or after a platinum based therapy
2,344 studies on the registry are indexed under Head and Neck Neoplasms; 552 are open to participants now.
This study's enrollment of 502 is above the median of 100 across 441 observational studies indexed under Head and Neck Neoplasms.
Browse Head and Neck Neoplasms studies →Bristol-Myers Squibb is the lead sponsor of 1,538 studies on the registry; 116 are open to participants now.
Of its 429 completed or terminated interventional studies of FDA-regulated products, 223 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
adult patients who are at least 18 years of age with the diagnosis of Squamous Cell Carcinoma Head and Neck that the physician has already decided to initiate a treatment with nivolumab for the first time.
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Participants diagnosed with recurrent or metastatic squamous cell carcinoma of the Head and Neck and whose physician has decided to initiate a treatment with Nivolumab for the first time for the treatment of SCCHN.
Biological: Nivolumab
Specified dose on Specific Days
Overall Survival
Time frame: 3 Years
Overall Survival within Sub groups
Time frame: 3 year
Progression-free survival (PFS)
Time frame: 3 Years
Overall response rate (ORR)
Time frame: 3 years
Best overall response rate (BORR)
Time frame: 3 years
Time to response (TTR)
Time frame: 3 years
Duration of response (DOR)
Time frame: 3 years
Incidents of Adverse Events (AEs)
Time frame: 3 years
Incidents of immune-related Adverse Events
Time frame: 3 years
Incident of treatment-related Adverse Events
Time frame: 3 years
Number of socio-demographic characteristics in adult patients with SCCHN
Time frame: 3 years
Number of clinical characteristics in adult patients with SCCHN
Time frame: 3 Years
Number of treatment characteristics in adult patients with SCCHN
Time frame: 3 Years
Functional Assessment of Cancer Therapy - Head & Neck (FACT-H&N) Score
Time frame: 3 Years
Quality of life of caregiver (CarGoQoL ) Score
Time frame: 3 Years
Supportive Care Needs Survey for Partners and Caregivers (SCNS-P&C) Assessment score
Time frame: 3 Years
European Quality of Life-5 Dimensions (EQ-5D) score
Time frame: 3 Years
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bristol-Myers Squibb